Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Weekly Research Analysts' Ratings Updates for Codexis (CDXS)
06:02pm, Monday, 17'th Feb 2020
Codexis (NASDAQ: CDXS) recently received a number of ratings updates from brokerages and research firms: 2/13/2020 – Codexis was downgraded by analysts at BidaskClub from a “sell” rating to a �
The "Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), by Technology (Gene Synthesis, Bioinformatics), by Application (Tissue Regeneration, Biofuel, Renewable Energy, Foo
$19.8B Synthetic Biology Market by Tools, Technology, Application and Region - Forecast to 2025
11:23am, Monday, 17'th Feb 2020
Dublin, Feb. 17, 2020 -- The "Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), by Technology (Gene Synthesis, Bioinformatics), by Application.
Brokerages Expect Codexis, Inc. (NASDAQ:CDXS) Will Announce Quarterly Sales of $21.05 Million
01:38am, Monday, 17'th Feb 2020
Equities research analysts predict that Codexis, Inc. (NASDAQ:CDXS) will post $21.05 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimate
Garrison Bradford & Associates Inc Buys The Carlyle Group Inc, Brookfield Asset Management ...
12:00am, Monday, 10'th Feb 2020Can You Imagine How Elated Codexis’s (NASDAQ:CDXS) Shareholders Feel About Its 386% Share Price Gain?
10:38am, Thursday, 06'th Feb 2020
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
ARK Investment Management LLC Grows Stock Position in Codexis, Inc. (NASDAQ:CDXS)
11:42am, Monday, 03'rd Feb 2020
ARK Investment Management LLC increased its holdings in Codexis, Inc. (NASDAQ:CDXS) by 8.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 683,855 shares of the
Have Insiders Been Buying Codexis, Inc. (NASDAQ:CDXS) Shares This Year?
12:52pm, Friday, 31'st Jan 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Codexis (NASDAQ:CDXS) Lifted to Strong-Buy at ValuEngine
07:28am, Friday, 31'st Jan 2020
Codexis (NASDAQ:CDXS) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Friday, ValuEngine reports. CDXS has been the subjec
Codexis (NASDAQ:CDXS) Rating Lowered to Sell at BidaskClub
07:28am, Friday, 31'st Jan 2020
Codexis (NASDAQ:CDXS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday, BidAskClub reports. Several other equities analysts h
Rubius launches early-stage study of lead drug in PKU
05:30pm, Thursday, 30'th Jan 2020
Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' (RUBY -4.5%) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketon
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
03:58pm, Tuesday, 28'th Jan 2020
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Codexis (NASDAQ:CDXS) Downgraded by Zacks Investment Research to "Hold"
10:40am, Monday, 27'th Jan 2020
Zacks Investment Research lowered shares of Codexis (NASDAQ:CDXS) from a buy rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, “Codexis is a leading prot
Codexis (NASDAQ:CDXS) Raised to Buy at Zacks Investment Research
11:18am, Sunday, 26'th Jan 2020
Zacks Investment Research upgraded shares of Codexis (NASDAQ:CDXS) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have
Codexis (NASDAQ:CDXS) Stock Rating Lowered by BidaskClub
09:56am, Sunday, 26'th Jan 2020
BidaskClub lowered shares of Codexis (NASDAQ:CDXS) from a buy rating to a hold rating in a research report report published on Wednesday morning, BidAskClub reports. A number of other research firms h
